Translate
Protalix Biotherapeutics, Inc. (de)
About
Protalix Biotherapeutics, Inc. (de) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 18 2026
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Mar 11 2026
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
Mar 9 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼
Jan 30 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Jan 30 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU